{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:50:04Z","timestamp":1792093804509,"version":"4.4.0"},"reference-count":38,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Taisho Pharmaceutical Co, Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acromegaly and gigantism are disorders caused by hypersecretion of growth hormone (GH), usually from pituitary adenomas. Although somatostatin analogues (SSA), dopamine agonists, and GH receptor antagonists are important therapeutic agents, all of these have issues with their effectiveness, safety, and\/or convenience of use. To overcome these, we developed a GH-specific potent neutralizing a mouse monoclonal antibody (mAb) named 13H02. 13H02 selectively bound both to human and monkey GH with high affinity, and strongly inhibited the biological activity of GH in the Nb2 rat lymphoma cell proliferation assay. In hypophysectomized\/GH-supplemented rats, a single subcutaneous administration of 13H02 significantly and dose-dependently lowered the serum insulin-like growth factor-1 levels. To pursue the therapeutic potential of this antibody for acromegaly and gigantism, we humanized 13H02 to reduce its immunogenicity and applied a single amino acid mutation in the Fc region to extend its serum half-life. The resulting antibody, Hu-13H02m, also showed GH-specific neutralizing activity, similar to the parental 13H02, and showed improved binding affinity to human FcRn.<\/jats:p>","DOI":"10.1210\/endocr\/bqae033","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T06:20:50Z","timestamp":1710829250000},"source":"Crossref","is-referenced-by-count":6,"title":["A Potent Neutralizing Monoclonal Antibody to Human Growth Hormone Suppresses Insulin-Like Growth Factor-1 in Female Rats"],"prefix":"10.1210","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8779-0750","authenticated-orcid":false,"given":"Tomoyuki","family":"Hata","sequence":"first","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikatsu","family":"Uematsu","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Sugita","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Adachi","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Kato","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Hirate","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei-ichiro","family":"Ishikura","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Kaku","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ohara","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kojima","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teisuke","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Saitama 331-9530 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"issue":"1\u20132","key":"2024042901110001800_bqae033-B1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cca.2005.06.009","article-title":"Growth hormone isoforms and segments\/fragments: molecular structure and laboratory measurement","volume":"364","author":"De Palo","year":"2006","journal-title":"Clin Chim Acta"},{"issue":"8","key":"2024042901110001800_bqae033-B2","first-page":"2878","article-title":"Cloning of two novel growth hormone transcripts expressed in human placenta","volume":"83","author":"Boguszewski","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2024042901110001800_bqae033-B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-019-0036-y","article-title":"Targeting growth hormone function: strategies and therapeutic applications","volume":"4","author":"Lu","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2024042901110001800_bqae033-B4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","article-title":"Prevalence and incidence of pituitary adenomas: a population based study in Malta","volume":"16","author":"Gruppetta","year":"2003","journal-title":"Pituitary"},{"issue":"3","key":"2024042901110001800_bqae033-B5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/EJE-16-0117","article-title":"Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study","volume":"175","author":"Dal","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2024042901110001800_bqae033-B6","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024042901110001800_bqae033-B7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"2024042901110001800_bqae033-B8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tem.2017.05.003","article-title":"Tumour-derived human growth hormone as a therapeutic target in oncology","volume":"28","author":"Perry","year":"2017","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"2024042901110001800_bqae033-B9","first-page":"411","article-title":"Current therapies and mortality in acromegaly","volume":"8","author":"G\u0103loiu","year":"2015","journal-title":"J Med Life"},{"issue":"12","key":"2024042901110001800_bqae033-B10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41574-018-0114-1","article-title":"The causes and consequences of pituitary gigantism","volume":"14","author":"Beckers","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2024042901110001800_bqae033-B11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2024042901110001800_bqae033-B12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024042901110001800_bqae033-B13","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024042901110001800_bqae033-B14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/B:PITU.0000044630.83354.f0","article-title":"Cabergoline therapy of growth hormone & growth hormone\/prolactin secreting pituitary tumors","volume":"7","author":"Freda","year":"2004","journal-title":"Pituitary"},{"issue":"16","key":"2024042901110001800_bqae033-B15","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"issue":"9295","key":"2024042901110001800_bqae033-B16","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"2024042901110001800_bqae033-B17","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024042901110001800_bqae033-B18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11102-013-0544-7","article-title":"Impact of treatment satisfaction on quality of life of patients with acromegaly","volume":"17","author":"Kepicoglu","year":"2014","journal-title":"Pituitary"},{"key":"2024042901110001800_bqae033-B19","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ijbiomac.2015.05.039","article-title":"Development and characterization of a novel GHR antibody antagonist, GF185","volume":"79","author":"Sun","year":"2015","journal-title":"Int J Biol Macromol"},{"key":"2024042901110001800_bqae033-B20","first-page":"538","article-title":"Humanization and characterization of a human growth hormone receptor (GHR) antagonist antibody RN172","volume":"35","author":"Siebel","year":"2014","journal-title":"Endocr Rev"},{"issue":"12","key":"2024042901110001800_bqae033-B21","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1210\/me.2004-0102","article-title":"A conformationally sensitive GHR [growth hormone (GH) receptor] antibody: impact on GH signaling and GHR proteolysis","volume":"18","author":"Jiang","year":"2004","journal-title":"Mol Endocrinol"},{"issue":"12","key":"2024042901110001800_bqae033-B22","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/0161-5890(82)90272-3","article-title":"Study of antigenic structure and inhibition of activity of human growth hormone and chorionic somatomammotropin by monoclonal antibodies","volume":"19","author":"Ivanyi","year":"1982","journal-title":"Mol Immunol"},{"issue":"4","key":"2024042901110001800_bqae033-B23","first-page":"1613","article-title":"Characterization of monoclonal antibodies specific for the human growth hormone 22K and 20K isoforms","volume":"81","author":"Mellado","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024042901110001800_bqae033-B24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0161-5890(95)00001-U","article-title":"Monoclonal antibodies to human growth hormone modulate its biological properties","volume":"32","author":"Roguin","year":"1995","journal-title":"Mol Immunol"},{"issue":"3","key":"2024042901110001800_bqae033-B25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/hyb.1996.15.211","article-title":"Monoclonal antibodies against recombinant human growth hormone as probes to study immune function","volume":"15","author":"Lattuada","year":"1996","journal-title":"Hybridoma"},{"issue":"11","key":"2024042901110001800_bqae033-B26","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1210\/jcem.85.11.6983","article-title":"A novel specific bioassay for serum human growth hormone","volume":"85","author":"Ishikawa","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024042901110001800_bqae033-B27","doi-asserted-by":"crossref","first-page":"e230071","DOI":"10.1530\/JME-23-0071","article-title":"Development and characterisation of a novel inhibitory anti-GH monoclonal antibody","volume":"72","author":"Lu","year":"2023","journal-title":"J Mol Endocrinol"},{"issue":"24","key":"2024042901110001800_bqae033-B28","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1073\/pnas.86.24.10029","article-title":"A humanized antibody that binds to the interleukin 2 receptor","volume":"86","author":"Queen","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024042901110001800_bqae033-B29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymeth.2005.01.007","article-title":"Design of humanized antibodies: from anti-Tac to Zenapax","volume":"36","author":"Tsurushita","year":"2005","journal-title":"Methods"},{"issue":"8","key":"2024042901110001800_bqae033-B30","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1074\/jbc.C300470200","article-title":"Engineered human IgG antibodies with longer serum half-lives in primates","volume":"279","author":"Hinton","year":"2004","journal-title":"J Biol Chem"},{"issue":"4","key":"2024042901110001800_bqae033-B31","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1210\/er.2011-1040","article-title":"Molecular mechanisms of prolactin and its receptor","volume":"33","author":"Brooks","year":"2012","journal-title":"Endocr Rev"},{"key":"2024042901110001800_bqae033-B32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1477-7827-2-51","article-title":"The prolactin and growth hormone families: pregnancy-specific hormones\/cytokines at the maternal-fetal interface","volume":"2","author":"Soares","year":"2004","journal-title":"Reprod Biol Endocrinol"},{"key":"2024042901110001800_bqae033-B33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tem.2010.08.004","article-title":"Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor","volume":"11","author":"Jacobson","year":"2010","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"2024042901110001800_bqae033-B34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2024042901110001800_bqae033-B35","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1210\/endo-123-2-1053","article-title":"Different effects of intermittent and continuous growth hormone (GH) administration on serum somatomedin-C\/insulin-like growth factor I and liver GH receptors in hypophysectomized rats","volume":"123","author":"Maiter","year":"1988","journal-title":"Endocrinology"},{"issue":"10","key":"2024042901110001800_bqae033-B36","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1210\/endo.137.10.8828490","article-title":"Recombinant human growth hormone (GH)-binding protein enhances the growth-promoting activity of human GH in the rat","volume":"137","author":"Clark","year":"1996","journal-title":"Endocrinology"},{"issue":"7","key":"2024042901110001800_bqae033-B37","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1211\/0022357021323","article-title":"A new animal model for evaluation of long-term growth rate over one month by rhGH\/PLGA microcapsule formulations","volume":"55","author":"Takada","year":"2003","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"2024042901110001800_bqae033-B38","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.4049\/jimmunol.0903296","article-title":"Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR","volume":"184","author":"Suzuki","year":"2010","journal-title":"J Immunol"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqae033\/57009214\/bqae033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/5\/bqae033\/57339877\/bqae033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/5\/bqae033\/57339877\/bqae033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T01:11:27Z","timestamp":1714353087000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqae033\/7631409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3,29]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqae033","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,3,19]]},"article-number":"bqae033"}}